Literature DB >> 29924960

p16/Ki-67 dual staining has a better accuracy than human papillomavirus (HPV) testing in women with abnormal cytology under 30 years old.

Laurențiu Pirtea1, Cristina Secosan, Madalin Margan, Lavinia Moleriu, Oana Balint, Dorin Grigoras, Ioan Sas, Florin Horhat, Adelina Jianu, Răzvan Ilina.   

Abstract

Due to a high rate of transient human papillomavirus (HPV) infection, HPV genotyping has a low specificity for high-grade cervical lesions, especially in young women. p16/Ki-67 dual immunocytochemical staining can also be used for the detection of oncogenic changes in cervical cells. Our aim was to compare the performance of p16/Ki-67 dual staining and HPV genotyping in the detection of high-grade cervical lesions in patients with atypical squamous cells of undetermined significance (ASCUS)/low-grade squamous intraepithelial lesion (LSIL) on Pap smear. We retrospectively analyzed 310 patients with ASCUS/LSIL on Pap smear, who underwent colposcopy. Among these, 161 patients with suspected lesions detected by colposcopy were referred for biopsy. HPV genotyping by LINEAR ARRAY HPV Genotyping Test (CE-IVD) and p16/Ki-67 dual staining by CINtec PLUS Cytology kit was performed prior to cervical biopsy. The overall sensitivity and specificity of HPV genotyping for the detection of cervical intraepithelial neoplasia (CIN) 2-3 was 79% and 72%, respectively in patients with ASCUS, and 85% and 64%, respectively in patients with LSIL. For p16/Ki-67 test, sensitivity and specificity rate was 66% and 93%, respectively in ASCUS and 59% and 79%, respectively in LSIL group. The specificity of p16/Ki-67 staining was significantly higher in both groups in patients aged <30 years compared to patients >30 years old (p < 0.001). Our results showed that p16/Ki-67 dual staining has a higher specificity compared to HPV genotyping, especially in patients under 30 years old. This indicates the usefulness of p16/Ki-67 testing in the triage of patients with ASCUS/LSIL and <30 years old, prior to referral for colposcopy and biopsy.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 29924960      PMCID: PMC6868483          DOI: 10.17305/bjbms.2018.3560

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  17 in total

1.  New technologies in cervical cytology screening: a word of caution.

Authors:  G F Sawaya; D A Grimes
Journal:  Obstet Gynecol       Date:  1999-08       Impact factor: 7.661

2.  Endothelial cell activation and proliferation in ovarian tumors: two distinct steps as potential markers for antiangiogenic therapy response.

Authors:  Laurenţiu Pirtea; Marius Raica; Anca Maria Cimpean
Journal:  Mol Med Rep       Date:  2012-02-28       Impact factor: 2.952

3.  Prospective evaluation of p16/Ki-67 dual-stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results.

Authors:  Christine Bergeron; Hans Ikenberg; Mario Sideri; Karin Denton; Johannes Bogers; Dietmar Schmidt; Francisco Alameda; Thomas Keller; Susanne Rehm; Ruediger Ridder
Journal:  Cancer Cytopathol       Date:  2015-04-17       Impact factor: 5.284

4.  Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri.

Authors:  R Klaes; T Friedrich; D Spitkovsky; R Ridder; W Rudy; U Petry; G Dallenbach-Hellweg; D Schmidt; M von Knebel Doeberitz
Journal:  Int J Cancer       Date:  2001-04-15       Impact factor: 7.396

5.  The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer.

Authors:  Sevilla Bălu; L Pirtea; Puşa Gaje; Anca Maria Cîmpean; M Raica
Journal:  Rom J Morphol Embryol       Date:  2012       Impact factor: 1.033

6.  Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.

Authors:  Elena Allia; Guglielmo Ronco; Anna Coccia; Patrizia Luparia; Luigia Macrì; Corinna Fiorito; Francesca Maletta; Cristina Deambrogio; Sara Tunesi; Laura De Marco; Anna Gillio-Tos; Anna Sapino; Bruno Ghiringhello
Journal:  Cancer Cytopathol       Date:  2014-12-22       Impact factor: 5.284

7.  HPV16 genotype, p16/Ki-67 dual staining and koilocytic morphology as potential predictors of the clinical outcome for cervical low-grade squamous intraepithelial lesions.

Authors:  D Vrdoljak-Mozetič; M Krašević; D Verša Ostojić; S Štemberger-Papić; R Rubeša-Mihaljević; M Bubonja-Šonje
Journal:  Cytopathology       Date:  2013-11-21       Impact factor: 2.073

8.  Age and HPV type as risk factors for HPV persistence after loop excision in patients with high grade cervical lesions: an observational study.

Authors:  Laurențiu Pirtea; Dorin Grigoraş; Petru Matusz; Marilena Pirtea; Lavinia Moleriu; Anca Tudor; Răzvan Ilina; Cristina Secoşan; Florin Horhat; Octavian Mazilu
Journal:  BMC Surg       Date:  2016-10-06       Impact factor: 2.102

9.  The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL.

Authors:  Júlio C Possati-Resende; José H T G Fregnani; Ligia M Kerr; Edmundo C Mauad; Adhemar Longatto-Filho; Cristovam Scapulatempo-Neto
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

10.  Human Papilloma Virus Persistence after Cone Excision in Women with Cervical High Grade Squamous Intraepithelial Lesion: A Prospective Study.

Authors:  Laurențiu Pirtea; Dorin Grigoraş; Petru Matusz; Marilena Pirtea; Lavinia Moleriu; Anca Tudor; Răzvan Ilina; Cristina Secoşan; Florin Horhat; Octavian Mazilu
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-05-12       Impact factor: 2.471

View more
  2 in total

Review 1.  Role of immunocytochemistry in cervical cancer screening.

Authors:  Vinod B Shidham
Journal:  Cytojournal       Date:  2022-06-14       Impact factor: 2.345

2.  Validation of CINtec® PLUS Cytology Kit in the Diagnosis of Persistent HPV Infections - Cohort Study in the Portuguese Population.

Authors:  Ângela L Abreu; Regina A Silva; Sílvia Fernandes
Journal:  J Cytol       Date:  2021-05-10       Impact factor: 1.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.